Peel Hunt Kept Motif Bio Plc (LON:MTFB) As Buy; Has Target Of GBX 106.00; Shorts at Xtl Biopharmaceuticals LTD. – American Depositary (XTLB) Lowered By 2.69%

Xtl Biopharmaceuticals LTD. – American Depositary (NASDAQ:XTLB) had a decrease of 2.69% in short interest. XTLB’s SI was 54,300 shares in April as released by FINRA. Its down 2.69% from 55,800 shares previously. With 8,500 avg volume, 6 days are for Xtl Biopharmaceuticals LTD. – American Depositary (NASDAQ:XTLB)’s short sellers to cover XTLB’s short positions. The SI to Xtl Biopharmaceuticals LTD. – American Depositary’s float is 1.27%. The stock increased 2.78% or $0.05 during the last trading session, reaching $1.8. About 150 shares traded. XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) has declined 17.65% since April 10, 2017 and is downtrending. It has underperformed by 29.20% the S&P500.

London: In an analyst report revealed on Tuesday morning, Peel Hunt restate their Buy rating on shares of Motif Bio Plc (LON:MTFB). They currently have a GBX 106.00 target price on the company. Peel Hunt’s target would indicate a potential upside of 218.99% from the company’s stock close price.

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company has market cap of $8.70 million. The Company’s lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and SjogrenÂ’s syndrome. It currently has negative earnings. The firm also develops recombinant human erythropoietin for the treatment of multiple myeloma patients.

The stock decreased 6.41% or GBX 2.285 during the last trading session, reaching GBX 33.365. About 552,501 shares traded. Motif Bio plc (LON:MTFB) has 0.00% since April 10, 2017 and is . It has underperformed by 11.55% the S&P500.

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company has market cap of 88.18 million GBP. The firm develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. It currently has negative earnings. The Company’s lead product candidate is Iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus.

Among 4 analysts covering Motif Bio Plc (LON:MTFB), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Motif Bio Plc has GBX 140 highest and GBX 90 lowest target. GBX 101.50’s average target is 204.21% above currents GBX 33.365 stock price. Motif Bio Plc had 89 analyst reports since July 23, 2015 according to SRatingsIntel. Beaufort Securities maintained the stock with “Speculative Buy” rating in Monday, November 21 report. The company was maintained on Thursday, November 16 by FinnCap. The rating was maintained by Beaufort Securities with “Speculative Buy” on Tuesday, August 25. Northland Capital maintained Motif Bio plc (LON:MTFB) on Friday, January 5 with “Buy” rating. The firm has “Buy” rating by Northland Capital given on Wednesday, November 11. FinnCap maintained Motif Bio plc (LON:MTFB) on Thursday, August 24 with “Buy” rating. Peel Hunt maintained the shares of MTFB in report on Wednesday, November 15 with “Buy” rating. The stock has “Buy” rating by Northland Capital on Tuesday, August 16. Northland Capital maintained it with “Buy” rating and GBX 114 target in Thursday, September 3 report. Northland Capital maintained the stock with “Buy” rating in Tuesday, October 13 report.